Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Medicenna Files $13M Financing at Deep Discount as Cash Dwindles and Stock Spirals
On May 22, 2026, Medicenna Therapeutics filed a prospectus supplement for a public offering of up to 10,000,000 units at $0.50 per unit (gross proceeds $3M–$5M), with each unit consisting of one common share and one-half of a warrant exercisable at $0.65 for three years. Concurrently, the company announced an $8M investment from Sorbie Bornholm LP and Sorbie Investments LLP through 16,000,000 units at the same $0.50/unit price, along with a complex equity‑swap “Sharing Agreement.” Under the swap, a notional $8M will be settled over 18 monthly tranches based on the company’s share performance versus a benchmark price. The sole agent is Bloom Burton Securities. The offering is expected to close on or about May 27, 2026. This news finalizes terms after a “marketed public offering” was launched on May 13 and terms were firmed on May 19.
The financing is deeply dilutive, priced at $0.50 per unit while the stock closed at $0.44 on May 21 – a discount to the offering price, signalling extremely weak demand and severe financial distress. Including the Sorbie placement, total gross proceeds could reach up to $13M, but the company’s cash of $10.6M at Dec. 31, 2025 only extended runway to Q3 2026, making this raise critical to avoid insolvency. The Sorbie equity‑swap adds another layer of potential dilution and share‑price sensitivity over 18 months. The terms suggest a company forced to accept unfavorable capital; this materially impairs shareholder value and confidence. The overall development, though providing a short‑term lifeline, is unequivocally negative and not a routine closing of a previously telegraphed financing.
Medicenna Therapeutics is a clinical‑stage immuno‑oncology company focused on novel Interleukin‑2 (IL‑2) Superkines. Its lead asset, MDNA11, is a long‑acting β‑enhanced not‑α IL‑2 Superkine in the Phase 1/2 ABILITY‑1 study for advanced solid tumors. Clinical data showed monotherapy ORR of 36–50% in expansion cohorts and a 43% ORR in combination with pembrolizumab in select settings, along with high disease‑control rates. A neoadjuvant trial (NEO‑CYT) in Stage III melanoma is underway. The company’s second key program, MDNA113, is a first‑in‑class tumor‑anchored, conditionally‑activated anti‑PD‑1 × IL‑2 bifunctional Superkine; it demonstrated favorable tolerability in non‑human primates and is expected to enter the clinic in late 2026. A legacy asset, bizaxofusp (MDNA55), targeting recurrent glioblastoma, showed a median OS of 13.6 months in a Phase 2b trial, though it is now being positioned for partnership.